References

Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation

10.1515/jtim-2025-0028 · 2025 · External reference

Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia

10.21147/j.issn.1000-9604.2024.05.06 · 2024 · External reference

Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group

10.21147/j.issn.1000-9604.2025.03.10 · 2025 · External reference

Advancements in diagnosis and treatments of acute leukemia

10.21147/j.issn.1000-9604.2026.03.09 · 2026 · External reference

A predicted model for refractory/recurrent cytomegalovirus infection in acute leukemia patients after haploidentical hematopoietic stem cell transplantation

10.3389/fcimb.2022.862526 · 2022 · External reference

Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group

10.1016/j.bbmt.2015.07.019 · 2015 · External reference

Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality

10.1016/j.cmi.2015.06.009 · 2015 · External reference

Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation

10.1056/nejmoa1706640 · 2017 · External reference

Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s2352-3026(23)00344-7 · 2024 · External reference

Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies

10.1016/s1473-3099(25)00069-6 · 2025 · External reference

Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation

10.1097/bs9.0000000000000178 · 2024 · External reference

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients

10.1002/iid3.431 · 2021 · External reference

Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation

10.1111/tid.13904 · 2022 · External reference

Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed-onset clinically significant cytomegalovirus infection after letermovir prophylaxis

10.1111/tid.14377 · 2024 · External reference

Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era

10.1093/cid/ciab298 · 2021 · External reference

Incidence of CMV replication and the role of letermovir primary/secondary prophylaxis in the early phase after allogeneic hematopoietic stem cell transplantation - A single centre study

10.21873/anticanres.14611 · 2020 · External reference

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data

10.1007/s00277-020-04362-2 · 2021 · External reference

Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant

10.1016/j.bbmt.2020.07.002 · 2020 · External reference

Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting

10.1182/bloodadvances.2021005637 · 2021 · External reference

Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis

10.1016/j.bbmt.2020.10.009 · 2021 · External reference

Letermovir administration to prevent cytomegalovirus reactivation is the potential risk of chronic graft-versus-host disease in patients who received haploidentical stem-cell transplantation with post-transplant cyclophosphamide

10.3389/fonc.2021.666774 · 2021 · External reference

Incidence of cytomegalovirus infection in Shanghai, China

10.1128/cvi.00385-08 · 2009 · External reference

Clinically significant EBV infection in allogeneic stem cell transplanted children receiving letermovir as primary CMV prophylaxis

10.1111/tid.70032 · 2025 · External reference

Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation

10.3324/haematol.2024.286265 · 2025 · External reference

Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis

10.1186/s40164-025-00665-0 · 2025 · External reference

Increased Epstein–Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation

10.1186/s13045-024-01612-y · 2024 · External reference

Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial

10.1016/j.scib.2021.06.002 · 2021 · External reference

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study

10.1182/blood-2015-02-627786 · 2015 · External reference

The role of collateral related donors in haploidentical hematopoietic stem cell transplantation

10.1016/j.scib.2018.08.008 · 2018 · External reference

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

10.1186/s13045-019-0781-y · 2019 · External reference

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological Malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

10.1016/s2352-3026(23)00342-3 · 2024 · External reference

Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study

10.1186/s40779-025-00640-0 · 2025 · External reference

Basiliximab for steroid-refractory acute graft-versus-host disease: a real-world analysis

10.1002/ajh.26475 · 2022 · External reference

Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide

10.1007/s00277-020-04273-2 · 2021 · External reference

Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation

10.1177/20406207211072838 · 2022 · External reference

Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World, Retrospective Multicenter Study (VAST Study)

10.1002/mco2.70942 · 2026 · External reference

Advancements in diagnosis and treatments of acute leukemia

10.21147/j.issn.1000-9604.2026.03.09 · 2026 · External reference

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

10.1016/j.bbmt.2009.06.019 · 2009 · External reference

Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study

10.1038/s41392-026-02889-w · 2026 · External reference

Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum

10.1093/cid/ciae321 · 2024 · External reference

The Chinese consensus on the management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation patients (2022)

10.3760/cma.j.issn.0253-2727.2022.08.001 · 2022 · External reference

Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

10.3324/haematol.2016.144428 · 2016 · External reference

Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings

10.1007/s00277-015-2423-y · 2015 · External reference

Haploidentical versus matched sibling donor HCT in racially diverse pediatric and AYA patients with hematologic Malignancies: a single-center comparison

10.1016/j.jtct.2025.09.014 · 2025 · External reference

Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia

10.1111/tid.13096 · 2019 · External reference

Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic Malignancies

10.1007/s00277-020-04156-6 · 2020 · External reference

Cytomegalovirus infection after allogeneic hematopoietic cell transplantation under 100-day letermovir prophylaxis: a real-world 1-year follow-up study

10.3390/v15091884 · 2023 · External reference

Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT

10.1038/s41598-025-27490-z · 2025 · External reference

Outcomes of refractory cytomegalovirus infection in the first year after allogeneic hematopoietic cell transplantation

10.1016/j.jtct.2022.04.016 · 2022 · External reference

Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies

10.1093/ofid/ofac687 · 2023 · External reference

Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation

10.1111/bjh.19451 · 2024 · External reference

Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study

10.59717/j.xinn-med.2023.100009 · 2023 · External reference

Basiliximab treatment for patients with steroid-refractory acute graft-versus-host disease following matched sibling donor hematopoietic stem cell transplantation

10.1177/09636897241257568 · 2024 · External reference

Vedolizumab provides a new hope of acute graft-versus-host disease prophylaxis through immune regulation

10.59717/j.xinn-med.2024.100083 · 2024 · External reference

Letermovir prophylaxis and cytomegalovirus reactivation in adult hematopoietic cell transplant recipients with and without acute graft versus host disease

10.3390/cancers13215572 · 2021 · External reference

Letermovir prophylaxis for CMV reactivation in allogeneic stem cell recipients: A retrospective single center analysis

10.21873/anticanres.16047 · 2022 · External reference

Letermovir for cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)

10.1038/s41409-024-02209-2 · 2024 · External reference

Letermovir at a prophylactic dose for cytomegalovirus infection in children undergoing allogeneic hematopoietic stem cell transplantation: A single-center retrospective study in Japan

10.1248/bpb.b24-00217 · 2024 · External reference

Letermovir prophylaxis for cytomegalovirus infection in children after hematopoietic cell transplantation

10.21873/anticanres.15848 · 2022 · External reference

Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection

10.1111/ajt.16450 · 2021 · External reference

Benefits of primary prophylaxis with letermovir in patients after allogeneic hematopoietic stem cell transplantation for hematologic Malignancies

10.1080/17474086.2025.2509876 · 2025 · External reference

Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation

10.1038/s41423-021-00829-y · 2022 · External reference

Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy

10.1002/ajh.26535 · 2022 · External reference

First-line therapy with donor-derived human cytomegalovirus (HCMV)-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation

10.1093/cid/ciz368 · 2020 · External reference

Virus-specific T-cell therapy for prophylaxis and treatment of cytomegalovirus infections after transplantation: a scoping review

10.1093/cid/ciaf232 · 2025 · External reference

Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients

10.1093/cid/ciaf410 · 2025 · External reference

Extended duration letermovir in allogeneic hematopoietic stem cell transplant

10.1016/j.trim.2023.101936 · 2023 · External reference

Real-world efficacy of extending duration of letermovir prophylaxis for allogeneic stem cell recipients

10.1111/tid.70116 · 2025 · External reference

The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis

10.1016/j.cmi.2025.08.017 · 2025 · External reference

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

10.1182/blood-2009-08-239186 · 2010 · External reference

Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation

10.1002/ajh.23452 · 2013 · External reference